Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Healthcare Biotechnology
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Waverley Pharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by NEMOMEIMPUNEon Apr 02, 2021 5:16am
321 Views
Post# 32931302

Well...MirrorWorldMan...

Well...MirrorWorldMan.......you could be on to something ...BUT... there is one comforting thing, digging a little bit deeper.

The mennonites. (https://en.wikipedia.org/wiki/Mennonites)

 This group of religeous people (beginning in the center of Europe 1630ies ), has tried to do the right things according to their belive system and Dr. Friesen was borne into this faith and still work in charities and institutions connected to the mennonites.
So I think he will handle his shares in a proper and meaningful way, not only for himselfe but also for the company and other shareholders that have a "faith" in this company.

I think there will be enough welth for all of us including Dr Friesen.

Best from Sweden

NEMO
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities